Professor David Nutt: Royal College of Psychiatrists President's Lecture

On 1 November 2018 cannabis products changed in legal status from a controlled drug without medical use to a Schedule 2 medicine has significantly implications for psychiatry. Some of these will be good, e.g. the potential to liberate new treatments for disorders such as schizophrenia and PTSD, but others may be bad such as the possible increased risk of psychotic experiences.

This talk will explore the facts around cannabis products and try to describe a sensible path for research and clinical interventions in this new era.